Director of Novo's antibiotics fund: Surprisingly few financing opportunities
After one year and four investments, Novo Holdings' Repair Impact Fund is starting to settle in the market, but has also been surprised by the companies' limited access to financing.
Last year, when Novo Holdings first engaged in the fight against antimicrobial resistance, the Danish investment firm was aware of the limited financing opportunities for new companies.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Minervax receives million-funding for new trial
For abonnenter
